1606 Corp - CBDW STOCK NEWS

GPO Plus (OTCQB:GPOX) has announced a strategic partnership with 1606 Corp (OTC PINK:CBDW) to enhance its PRISM+ platform with advanced AI capabilities. The collaboration aims to revolutionize distribution services for gas stations and convenience stores, a market generating over $327.6 Billion in annual in-store sales across 152,396 locations.

The partnership focuses on integrating AI solutions into GPOX's proprietary PRISM+ platform to optimize logistics, inventory management, and operational efficiencies. Key enhancements include AI-driven route optimization, predictive inventory management, retail insights, demand forecasting, and continuous performance monitoring.

GPOX's strategy targets the 15-20% of high-margin convenience store products not handled by major distributors. The partnership is already active, with AI development and integration underway to transform traditional distribution networks that currently operate on 10-30+ year-old technology stacks.

1606 Corp. (OTC PINK:CBDW) has announced a strategic partnership with GPO Plus, Inc. (OTCQB:GPOX) to enhance AI-driven distribution solutions. The partnership focuses on improving GPOX's PRISM+ platform through advanced AI services, targeting the gas station and convenience store industries.

Under the agreement, 1606 Corp will provide five key services: AI Development & Optimization, Data Integration & Analytics, Edge Computing, Training & Support, and Performance Monitoring & Optimization. The collaboration aims to optimize inventory management, streamline deliveries, and enhance operational excellence through real-time data-driven decisions.

The partnership is effective immediately, with development and implementation already underway. The integration focuses on leveraging diverse data sources, including IoT sensors, weather data, and satellite imagery, to drive actionable insights and improve customer satisfaction.

1606 Corp. (OTC Pink:CBDW), a leader in AI solutions, announces plans to leverage industry-wide cost reductions in data management and analytics to offer more affordable services. The company has successfully launched two specialized chatbot solutions in the past year: one for the CBD industry and another for public companies, priced at $99 per month.

The cost reductions enable 1606 Corp. to make sophisticated AI-driven technologies more accessible to smaller businesses, particularly in emerging industries like CBD. The company's solutions aim to improve customer engagement, streamline communications, and enhance operational efficiencies. The decreased costs in data management tools have helped reduce operational expenses, allowing the company to maintain competitive pricing while delivering high-quality solutions.

1606 Corp. (OTC Pink:CBDW) has expressed support for Adnexus Biotechnologies following their announcement of Trapicolast, a groundbreaking antimalarial drug developed using their AI-powered Sutra™ platform. The drug targets dual mechanisms within the Plasmodium parasite, specifically focusing on the apicoplast's DNA synthesis and vesicular trafficking pathways.

Trapicolast was developed by analyzing over 8 million molecular compounds through AI, resulting in the identification of ADX1 and ADX2 compounds. The drug's dual-target mechanism makes it particularly effective against drug-resistant malaria strains in regions like Sub-Saharan Africa and Southeast Asia.

While a previous Letter of Intent for strategic investment between 1606 Corp. and Adnexus terminated on November 28, 2024, both companies are continuing efforts to close the transaction. The development validates the potential of the Sutra™ AI platform in drug discovery, with Adnexus planning to advance the malaria drug in collaboration with partners in India.

1606 Corp. (OTC Pink:CBDW) has expressed strong support for Adnexus Biotechnologies' new Neural Temporal Fingerprinting technology, which combines AI-driven analysis of EEG and ECG signals for health monitoring. The technology focuses on neurological prediction for conditions like Alzheimer's and PTSD, and cardiovascular risk assessment for heart-related conditions.

While a previous Letter of Intent for strategic investment between the companies terminated on November 28, 2024, both parties are continuing efforts to close the transaction. The partnership aims to advance AI-powered healthcare solutions and position both companies for growth in the personalized medicine market.

1606 Corp. (OTC PINK:CBDW) reports progress in Q3 2024, focusing on AI chatbot market expansion and strategic partnerships. The company has filed its 10-Q for Q3 2024, maintaining current SEC filing status. Key developments include signing a Letter of Intent with Adnexus Biotechnologies for potential strategic investment in AI and biotechnology solutions. The company has created two chatbots (available at cbdw.ai) and plans to expand into e-commerce, finance, healthcare, and telecommunications sectors. Future focus includes closing the Adnexus investment, launching additional AI chatbot solutions, and expanding market presence.

1606 Corp (OTC PINK:CBDW) announces that its investment target Adnexus Biotechnologies has completed a merger agreement to acquire Sanctum Therapeutics' core technology assets for HIV and SARS-CoV-2 treatments. The merger combines Adnexus's AI-driven drug discovery platform with Sanctum's long-acting HIV capsid inhibitor and Adnexus's anti-HIV monoclonal antibodies. 1606 Corp has executed a Letter of Intent for a 5% strategic investment in Adnexus, with the LOI terminating on November 27, 2024.

1606 Corp. (OTC PINK:CBDW), a leader in AI chatbot solutions, is hosting an exclusive live investor webinar and Q&A session on October 10, 2024, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature CEO Austen Lambrecht discussing the company's innovative product portfolio and near-term expansion plans. Investors can register for free at the provided link and submit questions in advance to CBDW@redchip.com or during the live event.

1606 Corp. (OTC PINK:CBDW) has signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc., a company specializing in AI-driven drug discovery and infectious disease research. This potential investment aligns with 1606 Corp.'s goal to expand its AI capabilities and impact healthcare and biotechnology sectors.

Adnexus operates an advanced AI platform called SUTRA, which identifies specific sites and biomarkers for infectious and neurological diseases. The platform has successfully produced human monoclonal antibodies unaffected by virus mutations, utilizing data from 19 viruses, 8 million molecules, and human microbiome samples.

The collaboration aims to enhance technological capabilities and drive breakthroughs in drug discovery and infectious disease treatment. The transaction is subject to due diligence and certain conditions outlined in the LOI.